Preclinical Evidence of Alzheimer Changes: Convergent Cerebrospinal Fluid Biomarker and Fluorodeoxyglucose Positron Emission Tomography Findings

BACKGROUND: Alterations in cerebrospinal fluid (CSF) tau and β–amyloid peptide 1–42 (Aβ(42)) levels and rates of cerebral glucose (CMRglu) on fluorodeoxyglucose positron emission tomography (FDG PET) occur years before clinical symptoms of Alzheimer’s disease (AD) become manifest, but their relation...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Petrie, Eric C., Cross, Donna J., Galasko, Douglas, Schellenberg, Gerard D., Raskind, Murray A., Peskind, Elaine R., Minoshima, Satoshi
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2009
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2718788/
https://ncbi.nlm.nih.gov/pubmed/19433663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2009.59
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk